FDA Approves Drug to Prevent Joint Damage in Children with Haemophilia A
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Drug to Prevent Joint Damage in Children with Haemophilia A

ROCKVILLE, Md -- October 10, 2008 -- The US Food and Drug Administration (FDA) has approved a new use for antihemophilic factor recombinant (Kogenate FS) to reduce the frequency of bleeding episodes and prevent joint damage in children with haemophilia A.

"Administering [the drug] to children with haemophilia A on a daily basis before a bleeding event occurs will reduce bleeding into joints and help prevent joint damage, a major cause of disability in haemophiliacs," said Jesse Goodman, MD, FDA's Center for Biologics Evaluation and Research, Rockville, Maryland.

In a clinical trial, 65 boys aged less than 30 months with severe haemophilia A and normal joints were observed for 5 years. The patients received either 1 daily dose of the drug or 3 doses at the time of a bleeding episode.

Joint damage during a bleeding episode was 6-fold lower, and the rate of bleeding 8-fold lower, in those boys who received the drug on a daily basis compared with those who received the drug only when a bleeding episode occurred. Most patients received the drug intravenously through a catheter.

The most common adverse events were infection at the catheter site and fever.

SOURCE: US Food and Drug Administration

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities